Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Increasing HIV prevention access for Black women

Official title: Trauma-Informed HIV Prevention for Black Women in Baltimore

Run by Johns Hopkins Bloomberg School of Public Health · NCT06703060 · Data updated 2026-11-12

This study is testing a new way to help Black women in Baltimore start taking HIV prevention medication by providing support and resources to overcome challenges they face.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment300 (estimated)
SponsorJohns Hopkins Bloomberg School of Public Health
Academic / other
Locations1 site (Baltimore, Maryland)
StatusRecruiting
StartedFebruary 28, 2025
Main results expectedDecember 2027
Study endsFebruary 2028
Registry record updatedMarch 23, 2026
Trial IDNCT06703060 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are self-identified Black cisgender women who are HIV-negative, at least 18 years old, and have reported unprotected sex with male partners along with substantial HIV risk factors.

Probably not a fit

Patients who are non-English speaking or currently living with HIV will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to implement a multi-level intervention designed to enhance the initiation of pre-exposure prophylaxis (PrEP) among Black women in Baltimore, who are at high risk for HIV. The intervention addresses socio-structural barriers such as intimate partner violence and gendered racism that hinder access to PrEP. By utilizing peer navigation groups, the study seeks to provide support and resources to facilitate PrEP initiation among participants. The effectiveness, implementation, and sustainability of this approach will be assessed throughout the study.

Why it matters

Potential benefit: If successful, this study could significantly increase PrEP initiation rates among Black women, thereby reducing their risk of HIV infection.

How similar studies have gone: While there is limited research specifically targeting this demographic with a multi-level intervention, similar studies have shown promise in addressing barriers to PrEP access in other populations.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* self-identified Black cisgender woman;
* self-reported HIV-negative status, and
* ≥18 years.
* reports unprotected vaginal or anal sex in the past 6 months with a male sexual partner,
* have at least one substantial HIV risk factor in the past 6 months according to the 2021 Centers for Disease Control (CDC) PrEP Eligibility Guidelines (i.e., HIV-positive sexual partner, recent bacterial Sexually Transmitted Disease (STD), 2+ sex partners, history of inconsistent or no condom use, commercial sex work, and residing in high HIV prevalence area or network), and
* never taken PrEP

Exclusion Criteria:

* non-English speaking and
* currently living with HIV

Where it's running

  • Johns Hopkins Bloomberg School of Public Health
    Baltimore, Maryland, United States
    Recruiting

Study contacts

  • Principal investigator: Tiara C. Willie, PhD, MA — Johns Hopkins Bloomberg School of Public Health
  • Study coordinator: Tiara C. Willie, PhD, MA
  • Email: twillie2@jhu.edu
  • Phone: 410-614-2686

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.